Premium
Salicylamide metabolism in acute intermittent porphyria
Author(s) -
Song Chull S.,
Bonkowsky Herbert L.,
Tschudy Donald P.
Publication year - 1974
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1974154431
Subject(s) - salicylamide , glucuronidation , hydroxylation , acute intermittent porphyria , chemistry , glucuronide , sulfation , metabolism , porphyria , pharmacology , endocrinology , medicine , biochemistry , microsome , enzyme , organic chemistry
Salicylamide is metabolized in man by glucuronidation, sulfation, and hydroxylation. It was used to examine these three drug‐metaboliZing pathways in patients with acute intermittent porphyria (AIP). The over‐all rate of metabolism of salicylamide was significantly reduced in porphyric subjects, with a mean half‐life of 103 minutes in comparison to 72 minutes in normals. This was due largely to the reduced rate of conversion to the sulfate and hydroxyl derivatives. Glucuronidation was not significantly different although there was greater individual variation among porphyric subjects. Consequently, subjects with AIP excreted a larger fraction of salicylamide as its glucuronide. This reduction in the rate of hydroxylation may be related to clinical exacerbations precipitated in patients with AIP by drugs metabolized primarily by hydroxylation.